Peter Fuller at Hudson Institute

Professor Peter Fuller AM, NHMRC Senior Principal Research Fellow

Professor Fuller is a clinician-scientist and leading expert in endocrinology and molecular endocrinology. After completing his early research training at Melbourne’s Prince Henry’s Hospital’s Medical Research Centre under the supervision of Professor John Funder, Prof Fuller travelled to the US where he completed postdoctoral training at the Massachusetts General Hospital in Boston. In 1987, Prof Fuller returned to Australia as Wellcome Trust Australian Senior Research Fellow, later receiving the Eric Susman Prize from the Royal Australasian College of Physicians, the Society for Endocrinology Hoffenberg International Medal of the British Endocrine Society and the Excellence in Mentoring Award: Academic and Research, from the Royal Australasian College of Physicians.

Prof Fuller’s research interests lie primarily in understanding the molecular mechanisms of steroid hormone action with a focus on the adrenal steroid, aldosterone. His group also studies the molecular pathogenesis of granulosa cell tumours of the ovary as well as other aspects of endocrine oncology, including thyroid and breast cancers.

He serves on the Boards of the Cancer Council, the Victorian Cancer Agency as Deputy Chair and is Chair of the Cabrini Institute. He is also a Life Member of the Endocrine Society of Australia.

Prof Fuller’s international engagements include membership of both the Nominating and the Publications Committees of the Endocrine Society; he also serves on numerous editorial boards.

Selected publications

  • Chu S, Alexiadis M, Fuller PJ. Expression, mutational analysis, and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecologic Oncology, 108(1):182-90, 2008.

  • Rogerson FM, Yao YZ, Elsass RE,Dimopoulos N, Smith BJ, Fuller PJ. A critical region in the mineralocorticoid receptor for aldosterone binding and activation by cortisol: evidence for a common mechanism governing ligand binding specificity in steroid hormone receptors, Mol Endocrinol, Apr;21(4):817-28, 2007.

  • Rickard, A.J., Morgan, J., Tesch, G., Funder, J.W., Fuller, P.J. and Young, M.J. Deletion of mineralocorticoid receptors from macrophages protects against DOC/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54: 537-43, 2009.

  • Pippal, J. B., Yao, Y., Rogerson, F. M. and Fuller, P.J, Structural and functional characterisation of the interdomain interaction in the mineralocorticoid receptor, Molecular Endocrinology 23: 1360-1370, 2009.

  • Jamieson, S., Butzow, R., Andersson, N., Alexiadis, M., Unkila-Kallio, L., Heikinheimo, M., Fuller R, P.J. and Anttonen, M.The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary: independent confirmation from two centers. Modern Pathology 23:1477-85, 2010.

  • Pippal, J.P. Cheung, C.M.I., Yao, Y.Z., Brennan, F.E., and Fuller, P.J. Characterization of the zebrafish (Danio rerio) mineralocorticoid receptor. Molecular and Cellular Endocrinology . 332:58-66, 2011.

  • Alexiadis A, Eriksson N, Jamieson S, Davis M, Drummond A.E., Chu S., Clyne, C.D, Muscat, G.E, and Fuller, P.J. Nuclear receptor profiling of ovarian granulosa cell tumors. Hormones and Cancer 2:157-69, 2011.

  • Jamieson, S., and Fuller, P.J.Molecular pathogenesis of granulosa cell tumors of the ovary Endocrine Reviews 33: 109-144, 2012.

  • Muscat, G., Eriksson, N., Byth, K., LOI, S., Graham D., Jindal, S., Davis, M., Clyne, C., Funder, J.W., Simpson N, E.R., Ragan, M., Kuczek, E., Fuller, P.J., Tilley, W., Leedman, P. and Clarke, C. Nuclear receptors transcriptome: discriminant and prognostic value in breast cancer. Molecular Endocrinology, 27: 350-365, 2013.

  • Jamieson, S. and Fuller, P.J.Characterization of the inhibitor of kappaB kinase (IKK) complex in granulosa cell tumors of the ovary and granulosa cell tumor-derived cell lines. Hormones and Cancer, 4:277-292, 2013.

  • Clunning, C., Ward, B.K., Arulpragasam A., Fuller, P.J. and Ratajczak, T. The helix 1-3 loop in the glucocorticoid receptor LBD is a regulatory element for FKBP cochaperones. Molecular Endocrinology 27: 1020-1035, 2013.

  • Shen, J., Morgan, J., Tesch, G., Fuller, P.J. and Young M.J. CCL2-dependent macrophage recruitment is critical for mineralocorticoid receptor mediated cardiac fibrosis, inflammation and blood pressure responses in male mice. Endocrinology, 155:1057-1066, 2014.

  • Wong, P., Fuller, P.J., Gillespie, M.T., Kartsogiannis, V., Kerr, P.G., Doery, J.C.G., Paul, E., Bowden, D.K., Strauss, B.J. and Milat, F. Thalassemia bone disease: a 19 year longitudinal analysis. Journal of Bone and Mineral Research, 27:doi.10-1002/jbmr.2266 Epub ahead of print, 2014.

  • Mond, M., ALexiadis, M., Eriksson, N., Davis, M., Muscat, G., Fuller, P.J. and Gilfillan, C. Nuclear receptor expression in human differentiated thyroid tumors. Thyroid, 24:1000-1011, 2014.

  • Rogerson, F.M., Yao, Y-Z., Young, M.J. and Fuller, P.J. Identification and characterisation of a ligand-selective mineralocorticoid receptor coactivator. FASEB Journal, Epub ahead of print, 2014.

  • Yang, J., Fuller, P.J., Morgan, J., Shibata, H., McDonnell, D.P., Clyne, C.D. and Young, M.J. Use of phage display to identify novel mineralocorticoid receptor-interacting proteins. Molecular Endocrinology 28:1571-1584, 2014.